Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medications. With over $1.4 billion in global revenues, Lupin is currently the 14th largest generic pharmaceutical company in the world. Since the launch of its US generics division in December 2005, Lupin has introduced 42 new products in more than 200 dosage strengths and packaging sizes, covering many major therapeutic categories in the US market.
A Market Leader
Lupin is the leader in half of the products it markets, and as many as 35 of these 42 products are in the top 3 ranking by market share. Based on total prescriptions dispensed, Lupin is the 5th largest generic pharmaceutical company, and has been one of the fastest growing pharmaceutical companies for 3 consecutive years in the United States, according to IMS Health’s National Prescription Audit (MAT March 2012).
Robust, Growing Pipeline
Lupin’s sustained growth performance is not only measured in numbers, but also in its ability to continue to enter new segments and launch products that are first to market. Lupin introduced 13 new generic products in 2011, with 3 of those being oral contraceptives, a new category for the company. The company expects approvals for approximately 30 new oral contraceptives over the next few years. Lupin also introduced the first FDAapproved generic equivalent of Shionogi’s Fortamet®
(metformin HCl extended-release tablets).
The company was granted final FDA approval on 15 new products from January 2011 to July 2012. Lupin’s pipeline is entering into new therapeutic areas, such as dermatologics and oncology, and new dosage forms, such as ophthalmics and otics.
Lupin invested 7.5% of its net sales for R&D, which enables the company to create one of the best generic product pipelines in the world. From January 2011 to June 2012, the company filed 39 ANDAs with the FDA. Lupin continues to maintain its position as one of the top 10 ANDA filers for the US market, with 23 cumulative first-to-file opportunities for the US generics market.
In order to exceed the demand of the US generic pharmaceutical market, Lupin has expanded manufacturing capacities over the past several years at all of its best-inclass manufacturing facilities and continues to strengthen its efficient supply chain. New technological initiatives were also taken for energy conservation and environmental protection. All of these capital expenditures are focused on meeting the growing demands of Lupin’s customers.
The company’s focus on technology and differentiation enables it to charter new areas of business, such as unique therapeutic categories and difficult-to-manufacture drugs. Lupin is prepared with a rich pipeline consisting of niche products, first-to-files, and products requiring dedicated facilities or having high barriers to entry.
Lupin’s consistent track record of growth is a direct result of a valuable pipeline, solid customer relationships, and flawless execution. With a commitment to grow the company with new market entries, exciting new launches, and a series of strategic investments in acquisitions, Lupin Pharmaceuticals, Inc. remains dedicated to exceeding the expectations of its trade partners.
For more information, please visit www.lupinpharmaceuticals.com